PURPOSE: Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors. METHODS: Treatment consisted of RAD001 5 mg/d (30 patients) or 10 mg/d (30 patients) and octreotide LAR 30 mg every 28 days. Thirty carcinoid and 30 islet cell patients were enrolled. RESULTS: Intent-to-treat response rate was 20%. Per protocol, there were 13 with partial responses (22%), 42 with stable disease (SD; 70%), and five patients with progressive disease (8%). Overall median progression-free survival (PFS) was 60 weeks. Median PFS for patients with known SD at entry was longer than for those who had progressive disease (74 v 50 weeks; P < .01). Median overall survival has not been reached. One-, 2-, and 3-year survival rates were 83%, 81%, and 78%, respectively. Among 37 patients with elevated chromogranin A, 26 (70%) achieved normalization or more than 50% reduction. Most common toxicity was mild aphthous ulceration. Grade 3/4 toxicities occurring in >or= 10% of patients included hypophosphatemia (11%), fatigue (11%), and diarrhea (11%). Treatment was associated with a dose-dependent rise in lactate dehydrogenase (LDH). Those with lower than 109 U/L rise in LDH at week 4 had shorter PFS (38 v 69 weeks; P = .01). Treatment was also associated with a decrease in proliferation marker Ki-67 among patients who underwent optional paired pre- and post-treatment biopsy (P = .04). CONCLUSION: RAD001 at 5 or 10 mg/d was well tolerated in combination with octreotide LAR, with promising antitumor activity. Confirmatory studies are ongoing.
PURPOSE: Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors. METHODS: Treatment consisted of RAD001 5 mg/d (30 patients) or 10 mg/d (30 patients) and octreotide LAR 30 mg every 28 days. Thirty carcinoid and 30 islet cell patients were enrolled. RESULTS: Intent-to-treat response rate was 20%. Per protocol, there were 13 with partial responses (22%), 42 with stable disease (SD; 70%), and five patients with progressive disease (8%). Overall median progression-free survival (PFS) was 60 weeks. Median PFS for patients with known SD at entry was longer than for those who had progressive disease (74 v 50 weeks; P < .01). Median overall survival has not been reached. One-, 2-, and 3-year survival rates were 83%, 81%, and 78%, respectively. Among 37 patients with elevated chromogranin A, 26 (70%) achieved normalization or more than 50% reduction. Most common toxicity was mild aphthous ulceration. Grade 3/4 toxicities occurring in >or= 10% of patients included hypophosphatemia (11%), fatigue (11%), and diarrhea (11%). Treatment was associated with a dose-dependent rise in lactate dehydrogenase (LDH). Those with lower than 109 U/L rise in LDH at week 4 had shorter PFS (38 v 69 weeks; P = .01). Treatment was also associated with a decrease in proliferation marker Ki-67 among patients who underwent optional paired pre- and post-treatment biopsy (P = .04). CONCLUSION: RAD001 at 5 or 10 mg/d was well tolerated in combination with octreotide LAR, with promising antitumor activity. Confirmatory studies are ongoing.
Authors: G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann Journal: Virchows Arch Date: 2007-08-03 Impact factor: 4.064
Authors: James C Yao; Jun X Zhang; Asif Rashid; Sai-Ching J Yeung; Janio Szklaruk; Kenneth Hess; Keping Xie; Lee Ellis; James L Abbruzzese; Jaffer A Ajani Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531
Authors: Eric H Jensen; Larry Kvols; James M McLoughlin; James M Lewis; Michael D Alvarado; Timothy Yeatman; Mokenge Malafa; David Shibata Journal: Ann Surg Oncol Date: 2006-12-05 Impact factor: 5.344
Authors: In-Seon Choi; Marcos R H Estecio; Yasuhiko Nagano; Do Ha Kim; Jill A White; James C Yao; Jean-Pierre J Issa; Asif Rashid Journal: Mod Pathol Date: 2007-05-04 Impact factor: 7.842
Authors: Do Ha Kim; Yasuhiko Nagano; In-Seon Choi; Jill A White; James C Yao; Asif Rashid Journal: Genes Chromosomes Cancer Date: 2008-01 Impact factor: 5.006
Authors: Amy Moreno; Argun Akcakanat; Mark F Munsell; Alpana Soni; James C Yao; Funda Meric-Bernstam Journal: Endocr Relat Cancer Date: 2008-03 Impact factor: 5.678
Authors: James C Yao; Alexandria Phan; Paulo M Hoff; Helen X Chen; Chusilp Charnsangavej; Sai-Ching J Yeung; Kenneth Hess; Chaan Ng; James L Abbruzzese; Jaffer A Ajani Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Mizutomo Azuma; Michael Shi; Kathleen D Danenberg; Humphrey Gardner; Carl Barrett; Christian J Jacques; Andrew Sherod; Syma Iqbal; Anthony El-Khoueiry; Dongyun Yang; Wu Zhang; Peter V Danenberg; Heinz-Josef Lenz Journal: Pharmacogenomics Date: 2007-12 Impact factor: 2.533
Authors: Jun Yao; Jian-yao Wang; Yi Liu; Bin Wang; Ying-xue Li; Ru Zhang; Li-sheng Wang; Lei Liu Journal: Med Oncol Date: 2014-11-14 Impact factor: 3.064
Authors: Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin Journal: Langenbecks Arch Surg Date: 2011-01-28 Impact factor: 3.445
Authors: Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra Journal: Nat Rev Gastroenterol Hepatol Date: 2012-02-07 Impact factor: 46.802
Authors: Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Karen E Bullock; William P Petros; Islam Younis; Hope E Uronis; Michael A Morse; Gerard C Blobe; S Yousuf Zafar; Jon P Gockerman; Joanne J Lager; Roxanne Truax; Kellen L Meadows; Leigh A Howard; Margot M O'Neill; Gloria Broadwater; Herbert I Hurwitz; Johanna C Bendell Journal: Cancer Chemother Pharmacol Date: 2010-11-16 Impact factor: 3.333